US74276L1052
US74276L1052
PROCEPT BioRobotics Corporation
Loading chart...
Company Profile
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Latest News

Simply Wall St. • 10/08/2026
PROCEPT BioRobotics (PRCT) Could Be 70% Undervalued On Lawsuit And Board Change

The Fly • 10/07/2026
Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
MT Newswires • 10/07/2026
Barclays Initiates PROCEPT BioRobotics at Overweight With $30 Price Target

Simply Wall St. • 10/06/2026
Does New Director and Discounting Lawsuit Change The Bull Case For PROCEPT BioRobotics (PRCT)?

PR Newswire • 09/22/2026
THINK Surgical Appoints Rick McDowell as Vice President, Sales

Motley Fool • 08/18/2026
Procept BioRobotics CEO Buys 23,900 Shares Amid 48% Stock Decline. What Does This Tell Investors?
Related stocks
Key Metrics & Overview
Detailed metrics & financial data of the company
Company Profile
5
MetricsCountry
Region
Sector
Industry
🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data
7/7 Very High
5Y Volatility
64.4% p.a.
Max Drawdown (5Y)
-83.2%
Sharpe Ratio (5Y)
-0.27
Beta Factor
0.92
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (64.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -83.2% in the extended horizon.